Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $81.4545.

VERA has been the subject of several analyst reports. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Wedbush increased their price objective on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a research note on Friday, December 5th. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price on the stock in a report on Wednesday, March 11th. Finally, Bank of America upped their price target on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th.

Insider Buying and Selling

In related news, SVP Joseph R. Young sold 3,117 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $130,851.66. Following the completion of the sale, the senior vice president owned 64,722 shares of the company’s stock, valued at $2,717,029.56. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sean Grant sold 4,949 shares of Vera Therapeutics stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $207,759.02. Following the completion of the sale, the chief financial officer owned 114,181 shares of the company’s stock, valued at approximately $4,793,318.38. The trade was a 4.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 33,490 shares of company stock worth $1,405,910 over the last three months. Insiders own 16.30% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Vera Therapeutics by 7.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after acquiring an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Vera Therapeutics by 22.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after acquiring an additional 17,907 shares in the last quarter. Jane Street Group LLC grew its holdings in Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after purchasing an additional 62,678 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Vera Therapeutics in the second quarter valued at $237,000. Finally, Geode Capital Management LLC increased its stake in Vera Therapeutics by 7.7% in the second quarter. Geode Capital Management LLC now owns 1,294,958 shares of the company’s stock valued at $30,513,000 after purchasing an additional 92,149 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Trading Down 2.0%

Shares of VERA stock opened at $40.53 on Friday. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12. The stock has a market cap of $2.84 billion, a price-to-earnings ratio of -8.70 and a beta of 1.17. The stock has a 50-day moving average of $43.03 and a 200-day moving average of $37.48.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period in the prior year, the business earned ($0.72) earnings per share. On average, equities research analysts forecast that Vera Therapeutics will post -2.89 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.